when there the adult cases are treated ferociously with the result yielding Clinical trails,the pediatric ones are lagging behind by miles.
Hematologic malignancies, such as leukemia are one of the leading causes of cancer-related deaths in children. Basic, translational, and clinical research addressing early diagnosis, treatment, and prevention will be vital to improving survival.
Require the Psychosocial Standards of Care for Children with Cancer and Their Families, are an essential part of comprehensive cancer care, and ensure all cancer centers are able to meet those standards through various professions that provide them.
Currently, a DIPG diagnosis is a death sentence. There is no hope offered to families and 300-500 children die each year, and yet DIPG research is grossly underfunded. That is inexcusable.
Acute promyelocytic leukemia one of successfully treated leukemia using differentiation agent , instead of killing cancer cells, to promote them to be a normal cells, we can use this strategy in treatment of other type of leukemia
Pediatric cancers tend to be caused by arrested development, getting stuck in a progenitor state and failing to differentiate into quiescent cells. Turning cancer cells into harmless cells with differentiation therapy should be very effective.
The NIH/NCI have a reputation for funding "safe" research ideas - those with a high probability of success. The real breakthroughs in science come when we take big risks with the hope of big rewards. It is time.
In this exciting time of promise in cancer research, I suggest that we align the stakeholders in a collaborative effort to accelerate progress toward gentler treatments and cures for children. aPODD, a European non-profit, is an example of this.
Current intensified cancer treatment protocols lead to difficult short- and long-term side effects, especially for children with leukemia. In large-scale molecule screens, the zebrafish has proven effective in evaluating drug potency and toxicity.
I have talked about treatment cancer with Soulforce Medicine Show at:
I found some diffrences between pediatric and adult, but the case is little.
Pediatric brain tumors cannot be cured with radiation alone and may benefit from targeted therapies. The development of an ex vivo organoid-based platform will allow for "in vitro clinical trials" of radiation and tumor-specific targeted agents.
Successful studies in neuroblastoma, leukemia and melanoma as well as through utilization of PD-1 inhibitors has proven that harnessing the patient's own immune system is the future of oncology treatment.
Due to the blood brain barrier and inability to safely administer radiation therapy in young children, high dose chemotherapy must be given which has significant side effects and lacks efficacy. A more novel drug delivery system is required.
Recognize and address the major disparities in care and outcomes for adolescent and young adult (AYA) cancer patients as you set goals for the next phase of your work.